These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16292882)

  • 1. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents.
    Sakamoto JH; Smith BR; Xie B; Rokhlin SI; Lee SC; Ferrari M
    Technol Cancer Res Treat; 2005 Dec; 4(6):627-36. PubMed ID: 16292882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.
    Artemov D; Mori N; Okollie B; Bhujwalla ZM
    Magn Reson Med; 2003 Mar; 49(3):403-8. PubMed ID: 12594741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her-2/neu and breast cancer.
    Kaptain S; Tan LK; Chen B
    Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
    Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
    J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
    Jang M; Yoon YI; Kwon YS; Yoon TJ; Lee HJ; Hwang SI; Yun BL; Kim SM
    Korean J Radiol; 2014; 15(4):411-22. PubMed ID: 25053899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia.
    Zhang J; Dewilde AH; Chinn P; Foreman A; Barry S; Kanne D; Braunhut SJ
    Int J Hyperthermia; 2011; 27(7):682-97. PubMed ID: 21992561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers.
    Jiang Q; Hao S; Xiao X; Yao J; Ou B; Zhao Z; Liu F; Pan X; Luo B; Zhi H
    Breast Cancer; 2016 May; 23(3):445-55. PubMed ID: 25691133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct detection of herceptin/trastuzumab binding on breast tissue sections.
    Glazyrin A; Shen X; Blanc V; Eliason JF
    J Histochem Cytochem; 2007 Jan; 55(1):25-33. PubMed ID: 16957165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
    Hanna W; Kahn HJ; Trudeau M
    Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.